Plus   Neg

Stock Alert: AnPac Bio-Medical Gains On Test Volume, Optimistic Revenue Outlook

Shares of biotechnology company AnPac Bio-Medical Science Co., Ltd. (ANPC) are surging more than 90% Wednesday morning after the company reported strong demand for its cancer screening tests and set a record in paid test volume in the third quarter.

For FY20, the company sees revenue growth of 100% to $3 million to $3.3 million. Average selling price (ASP) of its cancer screening test in 2020 is expected to increase year-over-year contributing to a higher revenue growth forecast.

The Company plans to release its full year results in early March 2021.

ANPC is currently trading at $6.77. It has traded in the range of $3.15- $12.18 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT